Metastatic Lung Cancer Clinical Trials

14 recruiting

Metastatic Lung Cancer Trials at a Glance

13 actively recruiting trials for metastatic lung cancer are listed on ClinicalTrialsFinder across 6 cities in 19 countries. The largest study group is Phase 2 with 6 trials, with the heaviest enrollment activity in New York, Madrid, and Boston. Lead sponsors running metastatic lung cancer studies include Hospices Civils de Lyon, Hubei Cancer Hospital, and GFPC Investigation.

Browse metastatic lung cancer trials by phase

Treatments under study

About Metastatic Lung Cancer Clinical Trials

Looking for clinical trials for Metastatic Lung Cancer? There are currently 14 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Metastatic Lung Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Metastatic Lung Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 113 of 13 trials

Recruiting
Phase 1Phase 2

Safety and Efficacy of OBX-115 in Advanced Solid Tumors

Lung CancerMelanomaMetastatic Lung Cancer+2 more
Obsidian Therapeutics, Inc.208 enrolled9 locationsNCT06060613
Recruiting

Long-Terms Responders in Metastatic Lung Cancer: Better Understanding for Better Management (Lungevity Study)

Metastatic Lung CancerMetastatic NSCLCMetastatic Small Cell Lung Cancer
GFPC Investigation1,000 enrolled46 locationsNCT07243132
Recruiting
Phase 1Phase 2

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Non-small Cell Lung CancerMetastatic Lung CancerMetastatic Lung Non-Small Cell Carcinoma+18 more
Institut de Recherches Internationales Servier554 enrolled11 locationsNCT05786924
Recruiting
Phase 1

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

Metastatic Breast CancerAdvanced Breast CancerMetastatic Lung Cancer+6 more
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)392 enrolled36 locationsNCT06625775
Recruiting
Phase 1

A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors

Metastatic Breast CancerEndometrial CancerAdvanced Solid Tumor+6 more
Institut Paoli-Calmettes27 enrolled1 locationNCT05143970
Recruiting

Description of Neurocognitive and Psychiatric Disorders Associated With Targeted Therapies Used in the Treatment of Lung Cancers With ALK/ROS1 Fusion and Their Impact on Patients' Quality of Life: Construction of an Experimental Patient-researcher Collaborative Care and Research Pathway

Metastatic Lung CancerMetastatic Lung Cancer With ALK/ROS1 Fusion
Hospices Civils de Lyon20 enrolled2 locationsNCT06781905
Recruiting
Not Applicable

LIquid Biopsy to prEdict Responses To First-line immunotherapY in Metastatic Non-small Cell LUNG Cancer. LIBERTY LUNG

Metastatic Lung Cancer
Institut Curie300 enrolled3 locationsNCT04790682
Recruiting
Phase 2

Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation

Metastatic Lung CancerAdvanced NSCLC
Mirati Therapeutics Inc.90 enrolled166 locationsNCT05609578
Recruiting
Phase 2

Definitive Radiation for High-Risk Spine Metastases

Metastatic Breast CancerMetastatic CancerMetastatic Lung Cancer+5 more
Stony Brook University26 enrolled1 locationNCT06165419
Recruiting
Phase 1

Phase 1 Trial of SYNC-T - Immunotherapy for Patients With Advanced/Metastatic Solid Tumors

Metastatic Breast CancerCancerMetastatic Cancer+2 more
Williams Cancer Foundation20 enrolled1 locationNCT05544240
Recruiting

The Impact of Radiotherapy on Oligometastatic Cancer

Metastatic Breast CancerMetastatic Lung CancerMetastasis+2 more
Institut Investigacio Sanitaria Pere Virgili2,000 enrolled21 locationsNCT05933876
Recruiting
Phase 2

Single-drug Chemotherapy Plus Immunotherapy in Metastatic Non-small Cell Lung Cancer Elderly Patients

Metastatic Lung CancerElderly Patients
Hubei Cancer Hospital49 enrolled1 locationNCT06032052
Recruiting
Phase 2

Fecal Microbiota Transplantation With Immune Checkpoint Inhibitors in Lung Cancer

Metastatic Lung Cancer
Soroka University Medical Center80 enrolled2 locationsNCT05502913